FDA Investigator David K Glasgow

David K Glasgow has inspections in 6 countries as of 04 Aug 2023. David K Glasgow has collaborated with a combinined 1962 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
55
Last Inspection Date:
04 Aug 2023
Investigator Role:
FDA Investigator
Redica ID:
100007073
Country:
United States of America, Croatia, Czechia, Sweden, Spain, Brazil
Co-Investigator(s):
Adriana N Jimenez Lopez, Amanda M Osteen, Amber G Chung, Ana P Barido, Andrew R Wasko, Antoine Nel Hage, Arindam Dasgupta, PhD, Ashley M Whitehurst, Barbara J Holladay, Brandon L Mariner, Carla C Tuite, Carla J Lundi, Carol Mrivera Lopez, PhD, Carrie L Doupnik, Catherine Whiteside, PhD, Cecil D Mitchell, Charles A Snipes, PhD, Charles Kerns, Charles M Kerns, BLT DO, Chrissy J Cochran, Christine M Smith, Christine M Whitby, CSO, Christine Mwhitby Smith, Christine W Twohy, Courtney N Long, Ct Viswanathan, PhD, Cynthia A Harris, MD, RN, David L Chon, Dawn C Olenjack, Debra L Boyd Seale, Dennis R Downer, Dr. Abhijit Raha, PhD, Dr. Zhou Chen (nmi), MD PhD, Earl Echon, Edward E Lockwood (EEL), Edward P Potter, Emest F Bizjak, Emily A Green, Eric M Padgett, Erickson, Erin L Mcfiren, Erin M Mcdowell, Gerald W Miller, Hector J Colon Torres, Hugh M Mcclure, II, Jacqueline A O'shaughnessy, PhD, James D Planchon, James I Giefer, Jeanne D Shaffer, Jeffrey A Sommers, John A Iwen, John A Kadavil, PhD, John Dan, John J Walsh, John J Welsh, PhD, John Kadavil, PhD, Joseph D Gong, Jyoti B Patel, PhD, Karen C Daugherty, Karen M Montgomery (KMM), Kathleen B Swat, Kelly D Sheppard, Kenneth Nieves, La Tasha M Gunter, Ladislav Kermet, Lakisha M Williams, Linhart, Lisa Hayka, Lori S Lawless, LT Melanie M Mayor, USPHS, Lynette P Salisbury, Marya F Ricks, Meisha R Sampson, Meisha Waters, Melissa J Garcia, Michael F Skelly, PhD, Miguel A Martinez, Mra Davism, Nancy L Meade, Nicholas L Paulin, Pamela L Vega, Philip J Boston, Regina Gibson Melton, Rina Bhikha, Robert D Tollefsen, Robert J Nesselhauf, Ruark Lanham, Sarah Forney, Shafiq S Ahadi, Shavon L Square, Sherry L Secrist, BLT DO, Shusheen A Alexander, Simone E Pitts, Stacey A Priest, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Steven J Thurber, Susan J Essenmacher, Susanna E Ford, Analyst, Tamika E Allen, RN, Tania E Vizcaino, Tanika E Allen, RN, Tracy L Taras, William A Warnick, Young M Yoon

David K Glasgow's Documents

Publish Date Document Type Title
July, 2000 FDA 483 Response Covance Laboratories, Inc. - Form 483R, 2000-08-25
October, 2009 FDA 483 Danilo Hadoba M.D - Form 483, 2009-10-16
June, 2000 FDA 483 Cancer Treatment Centers of America - Form 483, 2000-06-23
February, 2000 EIR Brunt, Jane DVM - EIR, 2000-02-01
February, 2000 FDA 483 Response Johns Hopkins University School of Medicine IRB - Form 483R, 2000-03-29
February, 2000 FDA 483 Johns Hopkins University School of Medicine IRB - Form 483, 2000-02-25
October, 2009 EIR Danilo Hadoba M.D - EIR, 2009-10-16
February, 2000 EIR Johns Hopkins University School of Medicine IRB - EIR, 2000-02-25
November, 2002 FDA 483 Response Cambrex Karlskoga AB - Form 483R, 2002-11-07
November, 2002 EIR Cambrex Karlskoga AB - EIR, 2005-10-27
June, 2000 EIR Shabazz, Lloyd A - EIR, 2000-06-23
October, 2009 FDA 483 Response Danilo Hadoba M.D - Form 483R, 2009-11-05
June, 2000 FDA 483 Response Shabazz, Lloyd A - Form 483R, 2001-03-02
August, 2000 FDA 483 Ore Pharmaceuticals Inc - Form 483, 2000-08-29
March, 2000 FDA 483 Mersey Clinical Research, Inc. - Form 483, 2000-03-08
June, 2000 EIR Montag, Thomas W. - EIR, 2000-06-23
March, 2000 EIR Mersey,James H Dr Md - EIR, 2000-03-08
January, 2002 EIR Airgas-North Central Inc - EIR, 2002-01-29
July, 2000 EIR Covance Laboratories, Inc. - EIR, 2000-07-27
August, 2000 EIR Ore Pharmaceuticals Inc - EIR, 2000-08-29
April, 2000 EIR Papuchis, Gary Clinical Investigator - EIR, 2000-04-18
April, 2009 FDA 483 BASI Gaithersburg, LLC - Form 483, 2009-04-22
June, 2000 FDA 483 Cancer Treatment Centers of America - Form 483, 2000-06-23
July, 2000 FDA 483 Covance Laboratories, Inc. - Form 483, 2000-07-27

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more